Massachusetts Former Doctor Meal Ban Overturned

doctorThe physician/drug manufacturer relationship has largely been tainted in the past due to some drug companies going overboard by throwing huge expensive parties, sending doctors on vacations, etc. and all in the name of trying to sell a drug.

It was a problem that had gotten out of hand in the State of Massachusetts; therefore in 2008, restrictions were made to prohibit a company from wining and dining a doctor.

But, according to Boston.com Drug and medical device makers once again can treat Massachusetts doctors to meals and drinks in restaurants, ­under new regulations that weaken the state’s strict ban on gifts to health care providers.

The change drew strong criticism from the state’s major consumer advocacy group, but was applauded by the pharmaceutical industry’s national trade organization.

In July, Governor Deval Patrick signed a state budget that scaled back restrictions imposed in 2008 and allowed companies to pay for modest meals and refreshments for doctors as part of informational sessions about their products.  Patrick and the Legislature left it up to public health officials to define modest.  The state Public Health Council approved the new regulations in September.

Health officials did not ­establish a dollar limit. Instead, they decided that meals must be modest by local standards and “similar to what a provider may pay’’ for a meal when eating out, said Iyah Romm, director of policy, health planning, and strategic development for the Department of Public Health.

Romm said that is similar to rules adopted by the American Medical Association, the drug industry trade group PhRMA, and the Advanced Medical Technology Association.

Health Care for All, a consumer group based in Boston, called it a significant change that will increase health care costs, because money that companies spend on meals and ­alcohol gets rolled into the price of pharmaceutical products and devices. Food and drink is also used to attract physicians to sessions where companies promote expensive brand-name drugs, the group said.

“There are no holds barred on wining and dining again,” said the group’s executive director, Amy Whitcomb Slemmer. “Allowing these meals and inter­actions gets in the way of the doctor-patient relationship and affects prescribing behavior.’’

She said the organization would work to reverse the change.

One Public Health Council member, Dr. Alan Woodward, said he wants the final rules to make clear that lunch and dinner sessions have “valid education content’’ and “that this not be an open door for marketing.”

Patrick has maintained that the more permissive regulations are a “narrow change” that would facilitate efforts by companies to educate health care providers about new drugs and medical devices.

Marjorie Powell, senior ­assistant general counsel for PhRMA, said the Massachusetts law was placing unnecessary restrictions on the industry as it tries to work with health care providers.

“While physicians have a lot of sources of information, one important source is companies who are researching and bringing to market new medicines. They are tracking new uses and adverse events. To be able to tell doctors about that and other prescribers is important.’’

But Dr. Elizabeth Wiley, president of the American Medical Student Association, said the health department defined “‘modest meals’’ so vaguely that the state’s gift ban is now effectively unenforceable.

“As a leader in health care and medicine, it is disappointing that Massachusetts has given into the pressure from the pharmaceutical and medical device industries,’’ she said in a written statement. “This is a huge step backward in our effort to overhaul the health care system.”

 



, , , , , , ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.